ArticleFrontiers in nutrition2026
Growth, safety, and tolerance of a hydrolysed rice protein-based formula in infants with cow's milk allergy.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05618704 (A Single Arm, Open Label Intervention Study of a Hydrolyzed Protein Formula to Evaluate Growth, Safety and Tolerance in Infants With a Clinical Diagnosis of Cow's Milk Allergy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single Arm, Open Label Intervention Study of a Hydrolyzed Protein Formula to Evaluate Growth, Safety and Tolerance in Infants With a Clinical Diagnosis of Cow's Milk Allergy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cow's milk allergy (CMA) is the most common food allergy in infants, requiring the use of hypoallergenic formulas when breastfeeding is not possible. Hydrolysed rice formulas (HRF) are now positioned alongside extensively hydrolysed cow's milk protein formulas as first line (nutritional) management of CMA in both European and International guidelines. This descriptive single-arm, multicentre interventional study (NCT05618704) evaluated growth, safety, and tolerance of a new HRF in infants with CMA. Methods: Infants ≤8 months with CMA, diagnosed by their clinicians according to the local hospital practice, were recruited from clinics in Belgium, Poland and Spain. The infants ( Results: At baseline, mean age (±SD) was 3.17 ± 2.32 months. Over the 16-week period, increases in weight-for-age and weight-for-length were observed, with 92% of infants (56/61) meeting the predefined criteria for adequate growth. Sensitivity analyses in the AST population yielded consistent conclusions. Cow's milk related symptoms decreased over time; mean CoMiSS declined from 11.3 ± 3.4 at baseline to 2.1 ± 1.8 at 16 weeks, with reductions observed across all CMA diagnostic categories. Compared with baseline, parents reported reductions in gastrointestinal symptoms over the observation period. The overall parental opinion was that the formula was very good. No new safety signals were identified during the 16-week study period. Conclusion: Infants with clinician-diagnosed CMA who received the new HRF for 16 weeks showed adequate growth and reductions in cow's milk related and gastrointestinal symptoms over time. The formula was well tolerated by infants and well accepted by parents, and no new safety signals were observed during the study period. These findings support the use of HRF as a nutritional option for the dietary management of CMA, in line with current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.